BioCentury | Oct 7, 2013
Clinical News

Alefacept: Phase II data

...49 evaluable patients with newly diagnosed Type I diabetes showing that once-weekly 15 mg intramuscular alefacept...
...and the Juvenile Diabetes Research Foundation (JDRF). In 2011, Astellas voluntarily discontinued distribution of Amevive alefacept...
...April 10, 2006). Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan Product: Alefacept ( Amevive ) ( ASP045...
BioCentury | Jan 11, 2010
Strategy

Mulling over Biogen Idec's Future

...multiple sclerosis (MS) in 1996. In 2003, Biogen received approval of its second drug, Amevive alefacept...
BioCentury | Jan 11, 2010
Strategy

Evolution of Biogen Idec's Pipeline

...Idec Anti-LINGO-1 mAb MS Preclin Biogen Idec Anti-TWEAK mAb (BIIB023) RA Preclin Biogen Idec Amevive alefacept...
BioCentury | Feb 26, 2009
Distillery Therapeutics

Indication: Autoimmune disease

...include testing alefacept, which manipulates the CD58 pathway, in MS models. Astellas Pharma Inc.'s Amevive alefacept...
BioCentury | Jun 23, 2008
Regulation

The Pastiche of risk

...inhibitor Raptiva efalizumab from partners Genentech Inc. , Merck KGaA and Xoma Ltd. and Amevive alefacept...
BioCentury | Jun 23, 2008
Regulation

Ustekinumab vs. other biologics

...4, then every 12 wks Placebo 67% at 12 wks 76% 4% Approved treatments Amevive alefacept...
BioCentury | Oct 8, 2007
Product Development

PASI 75 comparisons

...placebo) 16 weeks Methotrexate 110 36% 16 weeks Placebo 53 19% 16 weeks Approved treatments Amevive...
BioCentury | Sep 17, 2007
Clinical News

Amevive alefacept: Phase II start

...of ASP045. The company acquired worldwide rights to the product, which it markets as Amevive alefacept...
...see BioCentury, April 10, 2006). Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan Product: Amevive alefacept ( ASP045...
BioCentury | Aug 21, 2006
Product Development

Challenging psoriasis biologics

...meta-analysis comparing its Daivobet ointment for severe psoriasis to Enbrel etanercept, Raptiva efalizumab and Amevive alefacept...
...four weeks achieved PASI 50 scores compared to 56%, 59% and 74% of patients receiving Amevive...
...by Genentech Inc. (DNA, South San Francisco, Calif.) and Serono S.A. (SWX:SEO; SRA, Geneva, Switzerland). Amevive...
BioCentury | Aug 21, 2006
Product Development

Psoriasis meta-analysis

...Psoriasis meta-analysis Daivobet/Taclonex Amevive Raptiva Enbrel PASI 50 88.8% 56.0% 59.0% 74.0% PASI 75 54.1% 28.0%...
Items per page:
1 - 10 of 282